{
    "nct_id": "NCT06704152",
    "official_title": "A Phase 1/2a Multicenter Ascending Dose Study to Evaluate the Safety of HA-1 Minor Histocompatibility Antigen-Reactive TCR-Modified T Cells (BSB-1001) in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDS",
    "inclusion_criteria": "1. Male or female patients, ages 18 - 70 years inclusive, undergoing alloHCT.\n2. Any Any of the following high-risk hematologic malignancies:\n\n   1. AML diagnosed which has been treated with at least two lines of therapy, and refractory or relapsed (CR, CRh or CRi,), including myeloblasts up to 25% OR MRD positive OR persistent disease-defining cytogenetic abnormality OR MRD-negative, but with high-risk disease\n   2. ALL which has been with abnormal lymphoblasts â‰¥5% and up to 25% in bone marrow OR persistent disease-defining cytogenetic abnormality or MRD positive\n   3. MDS after at least one line of therapy, which includes hypomethylating agent(s) and venetoclax and must be high or very high risk by Revised International Prognostic Scoring System (IPSS-R), monosomy, or complex karyotype or TP53 mutation.\n   4. In the expansion phase AML patients diagnosed which has been treated with at least two lines of therapy, and refractory or relapsed (CR, CRh or CRi,), including myeloblasts up to 25% OR MRD positive OR persistent disease-defining cytogenetic abnormality OR MRD-negative, but with high- risk disease\n3. HLA-A*02:01 AND HA-1 positive (either H/H or H/R).\n4. Suitable for one of the approved conditioning regimens as defined in the protocol.\n5. Patient must have an identified donor that is HA 1-negative with 10/10 matched related donor or 12/12 matched unrelated donor\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 70 Years",
    "exclusion_criteria": "1. Weight > 100 kg.\n2. Prior history of allogeneic or autologous stem cell transplantation.\n3. Previous genetically engineered chimeric antigen receptor T Cell therapy (CAR-T), approved or investigational, within 2 years of screening, with the exception of patients with ALL previously treated with an autologous CAR-T product.\n4. Treatment with other investigational agents within 5 half-lives of the planned dosing of BSB-1001 (day 0).\n5. History of treatment with checkpoint inhibitor therapy within 3 months of t transplantation.\n6. Other malignancy with life expectancy < 1year.\n7. Pregnant or lactating women.\n8. Uncontrolled bacterial, viral, or fungal infections at time of enrollment.\n9. Past or current viral infections as defined in the protocol.\n10. CNS involvement refractory to intrathecal chemotherapy and/or standard cranial- spinal radiation.\n11. Karnofsky Performance Score < 60%.\n12. Inadequate organ function as defined in protocol.",
    "miscellaneous_criteria": ""
}